EDSA vs. NNVC, PIRS, TRAW, TNXP, KPRX, ABVC, PPBT, VAXX, AYTU, and RDHL
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include NanoViricides (NNVC), Pieris Pharmaceuticals (PIRS), Traws Pharma (TRAW), Tonix Pharmaceuticals (TNXP), Kiora Pharmaceuticals (KPRX), ABVC BioPharma (ABVC), Purple Biotech (PPBT), Vaxxinity (VAXX), Aytu BioPharma (AYTU), and RedHill Biopharma (RDHL). These companies are all part of the "pharmaceutical preparations" industry.
Edesa Biotech (NASDAQ:EDSA) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.
5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 25.0% of Edesa Biotech shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, NanoViricides had 6 more articles in the media than Edesa Biotech. MarketBeat recorded 7 mentions for NanoViricides and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.67 beat NanoViricides' score of 0.42 indicating that Edesa Biotech is being referred to more favorably in the media.
Edesa Biotech presently has a consensus target price of $39.00, suggesting a potential upside of 762.83%. Given Edesa Biotech's higher possible upside, equities analysts plainly believe Edesa Biotech is more favorable than NanoViricides.
Edesa Biotech has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
NanoViricides' return on equity of -63.97% beat Edesa Biotech's return on equity.
Edesa Biotech received 25 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 75.76% of users gave Edesa Biotech an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
Summary
Edesa Biotech beats NanoViricides on 7 of the 12 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edesa Biotech Competitors List
Related Companies and Tools
